Premium
Mycophenolate mofetil for the prophylaxis of acute GVHD in HLA‐mismatched bone marrow transplant patients
Author(s) -
Basara N,
Blau WI,
Kiehl MG,
Schmetzer B,
Bischoff M,
Kirsten D,
Günzelmann S,
Fauser AA
Publication year - 2000
Publication title -
clinical transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 76
eISSN - 1399-0012
pISSN - 0902-0063
DOI - 10.1034/j.1399-0012.2000.140204.x
Subject(s) - medicine , mycophenolate , methotrexate , prednisolone , mycophenolic acid , human leukocyte antigen , tacrolimus , transplantation , bone marrow , gastroenterology , adverse effect , graft versus host disease , surgery , immunology , antigen
Mycophenolate mofetil (MMF), a new immunosuppressive drug successfully used in renal and heart transplant recipients, was used in combination with cyclosporin A (CsA), methotrexate (MTX) and prednisolone for the prophylaxis of acute graft‐versus‐host disease (aGVHD) after bone marrow transplantation (BMT) and peripheral blood stem cell transplantation (PBSCT) from human leukocyte antigen (HLA)‐mismatched, unrelated (n=9) and related donors (n=4) in an open single‐centre phase II study. Thirteen patients, transplanted from HLA‐mismatched donors of 18–57 yr of age, received 1 g MMF daily, starting at day 10, in addition to CsA and prednisolone for aGVHD prophylaxis. All patients were engrafted between days 13 and 15. Four of the 13 patients experienced aGVHD grade I/II (n=2) and grade III (n=2). All patients except 3 were alive on day 100 post‐transplantation. No severe adverse effects of MMF were recorded. In our pilot study, we demonstrated that MMF can be used safely for the prophylaxis of aGVHD.